Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L04AA56
|
| gptkbp:brand |
Tzield
|
| gptkbp:CASNumber |
287716-54-9
|
| gptkbp:developer |
gptkb:Sanofi
Provention Bio |
| https://www.w3.org/2000/01/rdf-schema#label |
teplizumab
|
| gptkbp:indication |
delay onset of stage 3 type 1 diabetes
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
humanized IgG1 kappa antibody
|
| gptkbp:mechanismOfAction |
anti-CD3 monoclonal antibody
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:lymphopenia
headache infections rash |
| gptkbp:target |
CD3 receptor
|
| gptkbp:UNII |
6O6C2GNZ6K
|
| gptkbp:usedFor |
type 1 diabetes
|
| gptkbp:bfsParent |
gptkb:anti-CD3_antibody
|
| gptkbp:bfsLayer |
7
|